develop
reagent
earli
diagnosi
therapeut
drug
sarsassoci
coronaviru
sarscov
larg
immun
human
antibodi
librari
construct
peripher
blood
mononuclear
cell
six
sar
convalesc
patient
singl
chain
variabl
fragment
antibodi
high
affin
n
protein
sarscov
isol
sequenc
analysi
reveal
vl
gene
compos
h
v
lambda
subgroup
region
vh
gene
compos
subgroup
region
solubl
antibodi
express
escherichia
coli
purifi
nienta
affin
chromatographi
verifi
sdspage
western
blot
potenti
applic
earli
diagnosi
evalu
use
n
protein
captur
elisa
antibodi
demonstr
high
sensit
activ
detect
n
protein
sarscov
final
potenti
use
antibodi
prophylaxi
vaccin
design
therapi
sar
discuss
sever
acut
respiratori
syndrom
sar
infecti
diseas
caus
outbreak
countri
spring
report
clinic
case
death
result
overal
mortal
rate
high
initi
clinic
sar
case
occur
independ
geograph
distinct
area
guangdong
find
determin
viral
sequenc
group
differ
subtyp
suggest
patient
infect
sarscov
multipl
sourc
rather
singl
sourc
therefor
possibl
sar
may
recurr
human
be
highlight
urgent
need
accur
time
diagnosi
sarscov
infect
prevent
anoth
global
outbreak
three
major
diagnost
method
current
avail
viral
rna
detect
use
realtim
revers
transcript
pcr
rtpcr
ii
antibodi
detect
use
elisa
iii
n
protein
detect
captur
elisa
although
rtpcr
use
assay
sometim
provid
falseposit
result
due
contamin
serolog
test
howev
provid
earli
diagnosi
sinc
sarscov
appear
blood
much
earlier
antibodi
identif
sarscovantigen
sera
provid
possibl
method
earli
diagnosi
sever
studi
found
n
protein
highli
immunogen
antibodi
respons
sar
patient
direct
frequent
predominantli
nucleocapsid
base
find
construct
singl
chain
antibodi
librari
isol
antin
protein
antibodi
earli
diagnosi
possibl
therapeut
use
pbmc
purifi
layer
ml
peripher
blood
donat
six
convalesc
sar
patient
ficollhypaqu
gradient
sigmaaldrich
loui
mo
total
rna
prepar
use
trizol
reagent
invitrogen
carlsbad
ca
accord
manufactur
instruct
mrna
purifi
total
rna
use
oligotex
mrna
purif
kit
qiagen
valencia
ca
use
first
strand
cdna
synthesi
use
random
hexam
promega
pittsburgh
pa
follow
standard
revers
transcript
protocol
primer
oligo
total
use
amplifi
variabl
region
heavi
vh
light
vl
chain
previous
describ
oligo
ad
conserv
region
end
introduc
restrict
site
tail
serv
anneal
sequenc
second
pcr
tail
vl
forward
vh
revers
primer
overlap
extens
pcr
tail
vl
revers
vh
forward
primer
serv
overlap
sequenc
linker
tail
shown
sequenc
font
underlin
anneal
match
sequenc
vl
forward
anneal
forward
primer
second
pcr
vl
revers
overlap
end
linker
vh
forward
overlap
end
linker
vh
revers
anneal
revers
primer
second
pcr
linker
tccggagggtcgaccataacttcgtataatg
pcr
perform
use
individu
forward
primer
mix
revers
primer
gel
purif
mg
vl
vh
equimol
linker
mix
ml
assembl
overlap
extens
pcr
use
condit
c
min
c
min
c
min
cycl
assembl
scfv
fragment
vl
linker
vh
amplifi
concurr
longer
tail
ad
order
facilit
subsequ
digest
restrict
enzym
primer
second
pcr
shown
second
vl
forward
tcaggtcactgcagactgattacggt
bsshii
second
vh
revers
gctacagctcagctacgtggagaatcc
nhei
twentyf
microgram
scfv
fragment
digest
nhei
bsshii
ligat
mg
gift
dr
bradburi
ligat
dna
electropor
escherichia
coli
cell
dna
ligas
inactiv
c
min
electropor
previous
describ
gener
higher
transform
effici
e
coli
compet
cell
transform
effici
transformantsmg
dna
prepar
previous
describ
librari
aliquot
store
c
store
bacteria
librari
inocul
fresh
medium
shaken
od
phagemid
librari
rescu
helper
phage
amersham
pharmacia
piscataway
nj
viral
rna
extract
trizol
reagent
invitrogen
carlsbad
ca
sarscov
biosafeti
level
iii
laboratori
sar
genom
rna
convert
cdna
revers
transcript
use
random
hexam
promega
pittsburgh
pa
code
region
sarscov
nucleocapsid
amplifi
pcr
use
result
cdna
pyrobest
polymeras
takara
dalian
liaon
sequenc
specif
primer
design
accord
publish
cdna
sequenc
sar
coronaviru
strain
genebank
access
primer
follow
forward
cgcggatccatgtctgataatg
revers
amplifi
dna
clone
bamhisali
recombin
plasmid
identifi
sequenc
nonfus
protein
express
vector
gift
institut
virolog
chines
academi
prevent
medicin
contain
p
r
p
l
tandem
promot
l
bacteriophag
high
level
express
restrain
gene
l
bacteriophag
adapt
heatinduc
express
recombin
plasmid
transform
e
coli
express
nucleocapsid
protein
induc
od
reach
addit
mm
isopropyllthiodgalactopyranosi
iptg
l
lb
broth
c
h
cell
harvest
centrifug
pellet
resuspend
lysi
buffer
ph
mm
tri
cell
ultrason
lyse
recombin
nucleocapsid
protein
purifi
two
step
employ
gel
filtrat
chromatographi
sephacryl
high
resolut
ionexchang
chromatographi
sp
sepharos
fast
flow
amersham
pharmacia
piscataway
nj
briefli
supernat
solut
appli
sephacryl
high
resolut
column
equilibr
buffer
ph
mm
tri
elut
nucleocapsid
protein
peak
collect
ph
adjust
solut
load
onto
sp
sepharos
fast
flow
column
equilibr
buffer
b
ph
mm
tri
nucleocapsid
protein
elut
buffer
c
ph
mm
tri
nacl
buffer
chang
pb
use
sephacryl
high
resolut
column
order
obtain
divers
scfv
possibl
employ
first
loos
stringent
pan
condit
enrich
scfvphage
n
protein
sarscov
brief
pan
procedur
perform
ml
plastic
tissu
cultur
flask
nunc
roskild
denmark
coat
purifi
nucleocapsid
protein
sarscov
ml
mgml
first
round
pan
mgml
follow
pan
carbonateebicarbon
buffer
ph
five
millilit
phage
librari
phage
ad
flask
block
mpb
pb
contain
nonfat
dri
milk
incub
room
temperatur
h
unbound
phage
remov
wash
pbst
pb
contain
tween
follow
wash
pb
wash
pbst
wash
pb
second
fourth
pan
ten
millilit
log
phase
od
e
coli
bacteria
ad
flask
allow
bound
phage
infect
c
min
without
shake
infect
bacteria
spread
yt
plate
contain
mgml
ampicillin
glucos
incub
c
overnight
phagemid
rescu
bacteria
helper
phage
use
next
pan
round
phage
coloni
form
unit
cfu
time
elut
titer
use
next
round
pan
one
scfvphage
could
isol
pan
copi
reach
four
round
select
perform
follow
last
select
round
individu
coloni
randomli
pick
plate
phagemid
rescu
identif
n
protein
bind
properti
phage
elisa
brief
four
elisa
plate
coat
purifi
sarscov
nucleocapsid
protein
mgwell
block
wash
ml
monoclon
scfvphage
supernat
ad
ml
mpb
incub
min
reduc
nonspecif
bind
absorb
supernat
ad
well
plate
incub
h
room
temperatur
plate
wash
bound
antibodi
detect
hrpconjug
antibodi
amersham
pharmacia
piscataway
nj
follow
incub
substrat
tmb
tetramethylbenzidin
absorb
measur
nm
evalu
sn
ratio
sampleneg
cut
valu
n
strong
posit
coloni
monoclon
phage
elisa
sequenc
select
scfvphage
introduc
e
coli
amersham
pharmacia
piscataway
nj
express
solubl
scfv
antibodi
presenc
mm
iptg
solubl
scfv
fuse
tag
cterminu
facilit
identif
western
blot
use
hrpconjug
antibodi
invitrogen
carlsbad
ca
purif
supernat
appli
nickelenitrilotriacet
acid
nienta
agaros
column
qiagen
valencia
ca
equilibr
pb
extens
wash
mm
imidazol
solubl
scfv
elut
mm
imidazol
follow
buffer
exchang
pb
use
gel
filtrat
chromatographi
affin
measur
use
noncompetit
elisa
describ
previous
beatti
lab
brief
plate
coat
n
protein
two
concentr
mgml
mgml
carbonateebicarbon
buffer
block
mpb
fourfold
serial
dilut
ad
well
start
concentr
nm
well
incub
hrpconjug
mous
monoclon
antibodi
follow
incub
tmb
substrat
solut
concentr
od
absorb
n
protein
coat
concentr
measur
k
aff
calcul
equat
ab
refer
concentr
od
n
protein
coat
concentr
mgml
ab
refer
concentr
od
n
protein
coat
concentr
mgml
microtit
plate
coat
mlwell
antin
protein
monoclon
antibodi
prepar
vector
gene
technolog
compani
concentr
mgml
carbonateebicarbon
buffer
plate
wash
block
mlwell
fourfold
serial
dilut
start
mgml
nucleocapsid
protein
ad
dilut
perform
normal
human
serum
concentr
run
duplic
h
incub
c
follow
six
wash
pbst
well
incub
mlwell
mgml
solubl
scfv
concurr
dilut
sar
convalesc
serum
previous
identifi
posit
reaction
nucleocapsid
protein
use
control
six
wash
pbst
nucleocapsid
protein
detect
hrpconjug
mous
monoclon
antibodi
hrpconjug
goat
anti
human
ig
bd
bioscienc
san
diego
ca
follow
incub
substrat
tmb
absorb
measur
describ
cut
valu
sn
twohundr
microgram
total
rna
obtain
pbmc
mg
mrna
isol
variabl
region
success
amplifi
assembl
vlelinkerevh
scfv
format
recombin
phagemid
transform
e
coli
yield
individu
clone
thirti
clone
pick
randomli
check
clone
effici
librari
pcr
result
show
clone
contain
fulllength
scfv
insert
ten
randomli
select
clone
sequenc
variabl
region
heavi
light
chain
fell
differ
famili
without
bia
accord
vbase
http
vbase
mrccpecamacuk
clone
cdna
fragment
encod
n
protein
sarscov
identifi
sequenc
ident
publish
sequenc
genebank
access
l
cultur
mg
purifi
nucleocpasid
protein
obtain
expect
purifi
nucleocapsid
protein
estim
approxim
kda
puriti
sdspage
first
round
pan
cfu
scfvphage
elut
titer
increas
growth
pan
round
cfu
second
cfu
third
pan
final
reach
cfu
fourth
pan
final
pan
round
scfvphage
clone
randomli
select
elisa
evalu
bind
activ
sarscov
nucleocapsid
protein
result
reveal
clone
gave
strong
posit
signal
od
valu
around
ten
clone
give
highest
signal
pick
sequenc
result
indic
clone
share
ident
sequenc
compos
bp
vl
gene
bp
vh
gene
fig
scfv
design
vl
vh
sequenc
analyz
compar
v
base
databas
human
antibodi
gene
databas
http
vbasemrccpecamacuk
immunoglobulin
blast
http
wwwncbinlmnihgovigblast
result
reveal
vl
gene
compos
h
v
lambda
subgroup
region
vh
gene
compos
subgroup
region
fig
signific
mutat
frame
region
complementar
determin
region
vh
vl
gene
except
mutat
p
site
kabat
number
vl
howev
high
degre
mutat
appear
region
sequenc
homolog
vl
closest
germlin
match
h
two
amino
acid
mutat
total
tabl
sequenc
homolog
vh
closest
germlin
match
long
sequenc
gywgsgyh
tabl
uniqu
result
mutat
rearrang
region
solubl
scfv
antibodi
express
e
coli
presenc
mm
iptg
c
overnight
express
supernat
whole
bacteria
protein
contain
high
concentr
solubl
scfv
antibodi
molecular
weight
kda
expect
western
blot
analysi
confirm
success
express
solubl
scfv
antibodi
fig
purif
result
scfv
antibodi
shown
fig
littl
scfv
appear
unbound
solut
mm
imidazol
wash
mm
imidazol
elut
scfv
antibodi
clearli
elut
migrat
singl
protein
band
sdspage
mg
purifi
obtain
l
cultur
absorb
curv
differ
n
protein
coat
concentr
shown
fig
ab
nm
ab
nm
calcul
softwar
curv
k
aff
therefor
calcul
lack
serum
sar
patient
use
serial
dilut
nucleocapsid
protein
normal
human
serum
check
whether
solubl
scfv
antibodi
could
use
detect
nucleocapsid
protein
sarscov
captur
elisa
result
indic
solubl
scfv
antibodi
could
detect
low
ngml
dilut
nucleocapsid
protein
captur
elisa
phage
display
antibodi
librari
use
power
tool
gener
monoclon
antibodi
viral
pathogen
includ
sarscov
scfv
antibodi
librari
display
filament
phage
synthet
deriv
nonimmun
immun
anim
human
among
immun
human
librari
resourc
obtain
high
affin
human
antibodi
human
antin
protein
antibodi
isol
sar
patient
report
studi
construct
larg
human
scfv
librari
peripher
blood
mononuclear
cell
six
convalesc
sar
patient
isol
one
scfv
antibodi
high
affin
nucleocapsid
protein
sarscov
interest
one
scfv
isol
larg
librari
member
good
divers
similar
result
report
isol
scfv
antibodi
sarscov
semisynthes
scfv
librari
reason
behind
result
may
isol
scfv
antibodi
competit
affin
advantag
pan
rapidli
wipe
other
stringent
pan
therefor
fewer
round
pan
would
help
get
divers
antibodi
round
stringent
pan
may
help
enrich
high
affin
antibodi
reduc
divers
time
present
studi
four
round
standard
pan
perform
popul
alreadi
overwhelm
would
advis
isol
scfvphage
second
third
round
pan
one
interest
obtain
divers
antibodi
instead
antibodi
highest
affin
analysi
sequenc
scfv
antibodi
reveal
mutat
either
light
heavi
chain
therefor
reason
believ
two
mutat
light
chain
especi
long
uniqu
sequenc
gywgsgyh
heavi
chain
due
rearrang
region
necessari
recognit
n
protein
epitop
standard
genet
mechan
vdj
rearrang
format
immunoglobulin
one
v
one
one
j
gene
segment
join
togeth
two
segment
appear
one
rare
phenomenon
dr
baskin
report
ded
fusion
one
could
observ
fetal
liver
well
adult
pbmc
previous
report
ded
fusion
could
result
error
vdj
rearrang
may
lead
increas
antibodi
divers
sever
studi
found
n
protein
highli
immunogen
thu
antibodi
respons
sar
patient
direct
frequent
predominantli
nucleocapsid
far
report
human
antibodi
sequenc
n
protein
sarscov
develop
sar
patient
studi
may
provid
use
inform
studi
human
humor
immun
sarscov
vaccin
develop
sever
studi
confirm
nucleocapsid
protein
captur
elisa
valuabl
method
earli
diagnosi
sarscov
infect
properti
scfv
antibodi
could
detect
n
protein
low
concentr
captur
elisa
make
potenti
use
reagent
sar
prophylaxi
treatment
furthermor
due
easi
rapid
cheap
product
may
good
substitut
monoclon
antibodi
antin
serum
unlik
antibodi
n
protein
play
neutral
role
due
intern
posit
virion
howev
research
report
monoclon
antibodi
mab
n
protein
murin
hepat
viru
mhv
anim
coronaviru
rotaviru
protect
effect
viru
infect
even
though
antibodi
lack
neutral
activ
latter
phenomenon
may
due
abil
iga
antibodi
enter
infect
cell
igatranscytosi
pathway
therebi
interf
viral
transcript
whether
scfv
antibodi
modifi
iga
format
fuse
iga
fc
fragment
similar
protect
effect
vivo
need
investig
summari
describ
isol
character
scfv
antibodi
demonstr
high
affin
n
protein
sarscov
scfv
antibodi
may
allow
better
understand
immunogen
characterist
n
protein
sar
vaccin
design
studi
viral
replic
antivir
activ
well
earli
diagnosi
potenti
therapi
sar
